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Edited by Peter BrzezinskiAbstract The key step of the ‘‘protonmotive Q-cycle’’ mecha-
nism for cytochrome bc1 complex is the bifurcated oxidation of
ubiquinol at the Qp site. ISP is reduced when its head domain
is at the b-position and subsequent move to the c1 position, to re-
duce cytochrome c1, upon protein conformational changes caused
by the electron transfer from cytochrome bL to bH. Results of
analyses of the inhibitory eﬃcacy and the binding aﬃnity, deter-
mined by isothermal titration calorimetry, of Pm and Pf, on dif-
ferent redox states of cytochrome bc1 complexes, conﬁrm this
speculation. Pm inhibitor has a higher aﬃnity and better eﬃcacy
with the cytochrome bH reduced complex and Pf binds better and
has a higher eﬃcacy with the ISP reduced complex.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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MOA-stilbene; Stigmatellin1. Introduction
The cytochrome bc1 complex (also known as ubiquinol–
cytochrome c oxidoreductase or complex III) is an important
segment of the electron transfer chain of mitochondria and
many respiratory and photosynthetic bacteria [1]. It catalyzes
electron transfer from ubiquinol to cytochrome c with con-
comitant translocation of protons across the membrane to
generate a proton gradient and membrane potential for ATP
synthesis [2].
Intensive biochemical and biophysical studies on this com-
plex [3–5] have led to the formulation of the ‘‘protonmotive
Q-cycle’’ mechanism for electron and proton transfer in the
cytochrome bc1 complex [6–8]. The presence of two separated
quinone/quinol binding domains, observed in recent X-ray
structural analyses of cytochrome bc1 complex [9–12], further
validate the ‘‘Q-cycle’’ mechanism. The key step of the Q-cycleAbbreviations: bc1, the cytochrome bc1 complex; bL, low potential
cytochrome b; bH, high-potential cytochrome b; ISP, iron–sulfur
protein; Qp, quinol oxidation site; Qn, quinol reduction site; Pm, Qp
inhibitors that facilitate the ISP head domain movement; Pf, Qp
inhibitors that ﬁx the ISP head domain at the b-position; MOAS,
(E)-b-methoxyacrylate-stilbene; Stig, stigmatellin; DM, N-dodecyl-b-
D-maltoside; QH2, ubiquinol and Q0C10BrH2, 2,3-dimethoxy-5-
methyl-6-(10-bromodecyl)-1,4-benzoquinol
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doi:10.1016/j.febslet.2008.01.016mechanism is the bifurcated oxidation of ubiquinol (QH2) at
the quinol oxidation site (Qp). It was postulated that the ﬁrst
electron of ubiquinol is transferred to the ‘‘high-potential
chain’’, consisting of iron–sulfur protein (ISP) and cytochrome
c1. Then the second electron of ubiquinol is passed through the
‘‘low-potential chain’’ consisting of cytochromes bL and bH, to
reduce ubiquinone or ubisemiquinone bound at the quinol
reduction site (Qn) [13,14]. Pre-steady state kinetic analysis
of cytochrome bL and ISP indicates that both are reduced by
ubiquinol at the same rate and the reduction of bH occurs be-
fore the reduction of cytochrome c1 [15–18]. Since the reduc-
tion of ISP by QH2 takes place when the head domain of
ISP is located at the b-position, a movement of head domain
to the c1-position is necessary for transfer electron to cyto-
chrome c1. It was speculated that protein conformational
changes caused by electron transfer from cytochrome bL to
bH facilitates the movement of the head domain of ISP [18–
20]. This speculation is supported by the fact that reduction
of cytochrome bH occurs before the reduction of cytochrome
c1 [15–18].
Based on the eﬀect on head domain movement of ISP, Qp
site inhibitors [21] can be divided into two groups: Pm, such
as MOAS, which enhances movement and Pf, such as stigma-
tellin, which ﬁxes the head domain at the b-position [19,22]. By
examining the redox state dependent inhibitory eﬃcacy of
these inhibitors, one can gain insight concerning the molecular
event that facilitates the movement of the head domain of ISP.
The cytochrome bc1 complex with a protein conformation
which keeps ISP at the b-position is expected to have a higher
inhibitory eﬃcacy for Pf inhibitors. On the other hand, a com-
plex with a protein conformation which facilitates (or allows)
head domain movement should bind Pm inhibitors better;
and has higher inhibitory eﬃcacy.
The results described in this report conﬁrm that when ISP is
in the reduced state and cytochrome bH is in oxidized state, the
complex binds Pf inhibitor better. When cytochrome bH is in
the reduced state, the complex binds Pm inhibitors better.
These results support the speculation that the driving force
for the movement of the reduced head domain of ISP is the
molecular event of electron transfer from bL to bH during the
catalytic cycle. It should be mentioned that the redox state
dependent binding of stigmatellin or MOAS to the cytochrome
bc1 complex has been investigated by several laboratories [23–
27]. A relative wide range of binding or dissociation constants
has been obtained with diﬀerent explanations. Determination
of an inhibitor binding or dissociation constant to a multi-sub-
unit lipoprotein complex, such as cytochrome bc1 complex, has
been a challenging work, as it depends very much on theblished by Elsevier B.V. All rights reserved.
524 X. Cen et al. / FEBS Letters 582 (2008) 523–526conditions of the preparation, the concentration of protein
used, the amount of phospholipid present, and the type of
detergent used. For the data comparison, it will only be valid
when the determination is done under the exactly same condi-
tions, as the data reported in this work.Fig. 1. Inhibitory titration of cytochrome bc1 complex with stigma-
tellin or MOAS. Diluted cytochrome bc1 complex, 0.1 mg/ml in 50 mM
Tris–HCl buﬀer, pH 8.0, containing 0.66 M sucrose and 0.01% DM
was incubated with various concentrations of stigmatellin (-d-) or
MOAS (-m-) at 0 C for 15 min before the activity of the treated
complex was determined. Activity of sample incubated with no
inhibitor was used as 100%. The data points are average values of
triplicate experiments. The deviation among the data of diﬀerent sets
of experiments is less than 5%.2. Materials and methods
2.1. Chemicals
Cytochrome c (horse, type III), sodium cholate, and deoxycholate
were purchased from Sigma. N-Dodecyl-b-D-maltoside (DM) was
from Anatrace. 2,3-Dimethoxy-5-methyl-6-(10-bromodecyl)-1,4-ben-
zoquinol (Q0C10BrH2) was prepared as previously reported (23).
Stigmatellin and MOAS were from Fluka. Stock solutions (10 mM)
of Stigmatellin and MOAS were made in 95% ethanol. The concentra-
tion was determined spectrophotometrically using millimolar extinc-
tion coeﬃcients of e267 nm = 65.5 cm
1 mM1 [21] and e338 nm =
26.5 cm1 mM1 [24] for stigmatellin and MOAS, respectively.
2.2. Cytochrome bc1 complex
Bovine heart mitochondrial cytochrome bc1 complex was prepared
as previously reported [28]. The puriﬁed complex contained 11 nmol
of cytochrome b and 5.6 nmol of cytochrome c1 per milligram of pro-
tein. Complex was dissolved in 50 mM Tris–HCl buﬀer, pH 8.0, con-
taining 0.66 M sucrose to a protein concentration of 32 mg/ml and
frozen at 80 C until use. The concentrations of cytochromes b and
c1 were determined spectrophotometrically using millimolar extinction
coeﬃcients of De562–575 nm = 28.5 cm
1 mM1 [29] and De552–540 nm =
17.5 cm1 mM1 [30] for cytochromes b and c1, respectively.
2.3. Activity assay
The cytochrome bc1 complex was diluted with 50 mM Tris–Cl buf-
fer, pH 8.0, containing 0.66 M sucrose and 0.01% DM to a protein
concentration of 0.1 mg/ml. Activity assays were carried out with
cytochrome bc1 complex at diﬀerent redox states. For partially re-
duced cytochrome b, the diluted solution was incubated with
10 mM sodium succinate for 15 h at 0 C, prior to assay. For re-
duced cytochrome c1, diluted complex was treated with 1 mM so-
dium ascorbate at 0 C for 15 min before assay. For the fully
oxidized sample, diluted complex was treated with a trace amount
of ferricyanide. Diluted complex solution (5 ll) was added to
995 ll of an assay mixture containing 100 mM phosphate buﬀer,
pH 7.4, containing 1 mM EDTA, 1 mM KCN, 100 lM cytochrome
c and 25 lM Q0C10BrH2. Activity was determined by measuring
the reduction of cytochrome c in a Shimadzu UV-2401PC spectro-
photometer at 23 C using a millimolar extinction coeﬃcient of
18.5 cm1 mM1 [30] for calculation. The non-enzymatic oxidation
of Q0C10BrH2 determined under the same conditions in the absence
of enzyme was subtracted from the assay. The bc1 complex used in
these experiments had a speciﬁc activity about 20 lmol cytochrome
c reduced/min/nmol cytochrome b.
2.4. Determination of inhibitor binding under diﬀerent redox states
The eﬃcacy of inhibitor binding to the cytochrome bc1 complex at
diﬀerent states of reduction was monitored by the inhibitory eﬀect of
a given inhibitor. The fully oxidized complex was incubated with var-
ious concentrations of MOAS and stigmatellin for 15 min at 0 C. The
concentration of inhibitor causing about 70% inhibition was selected
for inhibitory eﬃcacy studies. The concentrations selected for MOAS
and stigmatellin were 0.42/c1 and 0.40/c1, respectively. Diluted bc1
complex was mixed with MOAS or stigmatellin and incubated at
0 C. The activity of the inhibitor treated samples was assayed during
the course of incubation. Activities of diluted samples of diﬀerent re-
dox states, without inhibitor, were used as 100%.
2.5. Determination of inhibitor binding aﬃnity by isothermal titration
calorimetry
Determination of binding aﬃnity of stigmatellin or MOAS was car-
ried out by isothermal titration calorimetry using a CSC model 5300
ITC-III calorimeter. Cytochrome bc1 complex in the diﬀerent redox
states was dialyzed against 50 mM Tris–Cl buﬀer, pH 8.0, containing0.1% potassium deoxycholate and 10 mM succinate or 1 mM ascor-
bate, for 24 h, with two changes of buﬀer, at 4 C. The concentration
of protein was adjusted to 10 lM of cytochrome c1 using dialyzed buf-
fer. Inhibitor, 100 lM, was prepared using the ﬁnal dialyzed buﬀer.
Cytochrome bc1 complex was loaded into the 1.0 ml sample cell and
inhibitor (stigmatellin or MOAS) was loaded into the 250 ll syringe.
Ten microlitre aliquots of inhibitor were injected into the protein solu-
tion while the temperature of the system was maintained at 25 C. Inte-
gration of the heats over the time course of the experiment; the amount
of heat change (lJ) in each peak was plotted against the mole ratio of
inhibitor to cytochrome bc1 complex. The binding constant (Ka) of
each inhibitor to diﬀerent redox state of cytochrome bc1 complex
was calculated by iterative approximation. These calculations are de-
scribed in detail in the report of Eatough et al. [31], and are performed
automatically with the Bindworks software supplied with CSC ITC
instruments.3. Results and discussion
3.1. Pf and Pm inhibitor concentration dependent inhibition of
cytochrome bc1 complex
Aliquots of diluted cytochrome bc1 complex in the oxidized
state were incubated with various concentrations of inhibitor
at 0 C for 15 min before the activity of the mixtures were as-
sayed. Fig. 1 shows the titration of cytochrome bc1 complex
with Pf inhibitor, stigmatellin (-d-) and Pm inhibitor, MOAS
(-m-). The 100% speciﬁc activity represents the activity ob-
tained from a sample incubated in the absence of inhibitor,
20 lmoles cyt. c reduced/nmole cyt. b/min. As expected, activ-
ity decreased as the concentration of inhibitor increased. Max-
imum inhibition is observed when the concentration of
stigmatellin or MOAS approaches 0.5 mol per mol of bc1 com-
plex. Similar results were observed in the yeast cytochrome bc1
complex [32].
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eﬃcacy of Pf and Pm inhibitors
To determine the binding and inhibition eﬃcacy of a given
inhibitor, one should use a concentration of inhibitor that
causes less than 100% inhibition. Diluted cytochrome bc1 com-
plexes, 5 lM cytochrome c1, in diﬀerent redox states, were
treated with 2 lM inhibitor at 0 C. The activity of the treated
samples was determined at diﬀerent incubation times, 0–
15 min (see Fig. 2). The activity of the sample with no inhibitor
was used as 0 incubation time and as 100%. The curves with
circles (-s-) show the inhibitory eﬃcacy of Pm inhibitor,
MOAS (Fig. 2A) and Pf inhibitor, stigmatellin (Fig. 2B) on
oxidized cytochrome bc1 complex. The curves with crosses
(-·-) are for the ascorbate reduced complex and the curves with
triangles (-n-) are for the succinate reduced sample. Since theFig. 2. Time dependent inhibitory eﬃcacy of stigmatellin or MOAS on
cytochrome bc1 complex at diﬀerent redox states. Five lM cytochrome
bc1 complex, fully oxidized (-s-), ascorbate-reduced (-·-) or succinate-
reduced (-n-), was incubated with 2.1 lM MOAS (A) or 2.0 lM
stigmatellin (B). The activities of incubated samples were determined.
The activity of a sample incubated with no inhibitor was used as time
zero. No activity loss was observed during the 15 min incubation at
0 C. The data points are average values of triplicate experiments. The
deviation among the data of diﬀerent sets of experiments is less than
5%.purity of cytochrome bc1 complex used in this study is very
high, only a trace amount of succinate–ubiquinone oxidore-
ductase is present. Hence, overnight incubation with 10 mM
succinate is needed for cytochrome bH reduction. It should
be noted that in the succinate reduced complex, sample with
3-min incubation always shows a slightly higher inhibition
than the four minutes one, no explanation for this unusual
behavior is available now.
It has been reported that the binding of Pm inhibitors, such
as MOAS or myxothiazol, enhances movement of the head do-
main of ISP [19]. Thus a complex having a conformation sim-
ilar to that of the Pm bound one would be expected to bind
such inhibitor better and have a higher inhibitory eﬀect. As
indicated in Fig. 2A, the bc1 complex with reduced cytochrome
bH binds MOAS better than the ascorbate reduced or oxidized
state, suggesting that when cytochrome bH is in the reduced
state movement of the head domain of ISP is facilitated. On
the other hand, the stronger binding and higher inhibition of
Pf when ISP is in the reduced state indicates that, under this
condition, movement of head domain is retarded.
It is worth mentioned that when a less than stoichiometric
amount of inhibitor is used, it needs more than 10 min of incu-
bation at 0 C to reach maximum inhibition. Apparently the
slow reaction might have to do with low incubation tempera-
ture and the involvement of detergent and phospholipid in
the system. The incubation time is shorter if the system is incu-
bated at a higher temperature (data not shown).
Since both ascorbate and succinate reduced cytochrome bc1
complexes have cytochrome c1 in the reduced state (Fig. 2B),
the diﬀerence in inhibitor binding observed might be due to
cytochrome c1. To test this further, cytochrome bc1 complex
with only ISP in the reduced state was prepared. Cytochrome
bc1 complex was ﬁrst reduced by a limited amount of ascorbate
to give 50% cytochrome c1 reduction, at pH 8. The pH of the
partially reduced complex was adjusted to 7.0, under which
condition ISP will become mostly reduced and cytochrome
c1 mostly oxidized [33]. The Pf inhibitor eﬃcacy was then
determined. The results show that the Pf eﬃcacy for the com-
plex with only ISP reduced is similar to that for a complex in
which both cytochrome c1 and ISP are reduced, suggesting
that the redox state of cytochrome c1 has little to do with Pf
inhibitor binding (data not shown).
By ﬂuorescence quenching titration the dissociation con-
stants (Kd) for MAOS binding to cytochrome bc1 complex at
diﬀerent redox states have been reported [27]. The oxidized
complex has a smaller Kd than that of ascorbate or dithionite
reduced complex, suggesting that MOAS binds oxidized com-
plex better than the reduced form. This is inconsistent with the
results obtained by activity titration described in the previous
section. Since the binding of MOAS to cytochrome bc1 com-
plex was reported to be unaﬀected by the removal of ISP from
the complex (implying that binding is independent of the activ-
ity of the preparation) [24], the discrepancy might be due to the
diﬀerent preparations used and the diﬀerent detergent in-
volved.
3.3. Comparison of the binding constant of Pm and Pf inhibitors
to cytochrome bc1 complex under diﬀerent redox states
Table 1 summarizes the binding constants of MOAS and
stigmatellin to cytochrome bc1 complex under diﬀerent redox
states. MOAS binds much stronger to the succinate reduced
state than to the oxidized or ascorbate reduced state. On the
Table 1
Binding constant Ka (M
1) of stigmatellin or MOAS to cytochrome
bc1 complex at diﬀerent redox states
Redox state Ka (M
1)
Stigmatellin MOAS
Fully oxidized 1.43 ± 0.07 · 106 8.80 ± 0.44 · 103
Ascorbate reduced 3.51 ± 0.17 · 106 2.17 ± 0.11 · 104
Succinate reduced 2.77 ± 0.13 · 106 6.32 ± 0.32 · 104
526 X. Cen et al. / FEBS Letters 582 (2008) 523–526other hand, stigmatellin binds better to the ascorbate reduced
state than to oxidized state. These results are consistent with
the inhibitory eﬃcacies described in the previous section. Sev-
eral binding aﬃnity studies of MOAS and stigmatellin have
been reported previously [24,25,27]. The values for Kd or Ka
obtained are not always consistent, apparently due to the
determination method and preparation used.
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